TY - JOUR
T1 - Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling
AU - Zhang, Yong
AU - Won, Suk Hyun
AU - Jiang, Cheng
AU - Lee, Hyo Jeong
AU - Jeong, Soo Jin
AU - Lee, Eun Ok
AU - Zhang, Jinhui
AU - Ye, Min
AU - Kim, Sung Hoon
AU - Lü, Junxuan
N1 - Funding Information:
This work was supported, in part, by Hormel Foundation, NIH grant CA136953, Korean Medical Research Center (MRC) grant (No. 2009-0063466) and TTUHSC School of Pharmacy startup fund. We thank Mr. Todd Schuster at Hormel Institute for help with flow cytometric analyses.
PY - 2012/6
Y1 - 2012/6
N2 - Purpose: To test whether tanshinones inhibit prostate cancer (PCa) growth at least in part through inhibiting androgen receptor (AR) signaling. Methods: We evaluated cell growth, survival and AR signaling parameters of PCa cells after exposure to tanshinones in in vitro models. We also tested the in vivo inhibitory efficacy of tanshinone IIA (TIIA) against LNCaP xenograft model in athymic nude mice. Results: For androgen-dependent LNCaP cells, a colony growth assay showed strong inhibitory potency following the order of TIIA≈cryptotanshinone>tanshinone I, being 10-30 folds higher than Casodex (racemic). TIIA inhibited growth of LNCaP cells more than several androgen-independent PCa cell lines. All 3 tested tanshinones were devoid of AR agonist activity under castrate condition. Mechanistically, tanshinones inhibited AR nuclear translocation within 2 h, decreased protein and mRNA abundance of AR and its target prostate-specific antigen within 12 h, and stimulated proteosomal degradation of AR. Oral administration of TIIA (25 mg/kg, once daily) retarded LNCaP xenograft growth and down-regulated tumor AR abundance in athymic nude mice. Conclusion: AR targeting action of tanshinones was distinct from Casodex and contributed to prostate cancer growth suppression in vitro and in vivo.
AB - Purpose: To test whether tanshinones inhibit prostate cancer (PCa) growth at least in part through inhibiting androgen receptor (AR) signaling. Methods: We evaluated cell growth, survival and AR signaling parameters of PCa cells after exposure to tanshinones in in vitro models. We also tested the in vivo inhibitory efficacy of tanshinone IIA (TIIA) against LNCaP xenograft model in athymic nude mice. Results: For androgen-dependent LNCaP cells, a colony growth assay showed strong inhibitory potency following the order of TIIA≈cryptotanshinone>tanshinone I, being 10-30 folds higher than Casodex (racemic). TIIA inhibited growth of LNCaP cells more than several androgen-independent PCa cell lines. All 3 tested tanshinones were devoid of AR agonist activity under castrate condition. Mechanistically, tanshinones inhibited AR nuclear translocation within 2 h, decreased protein and mRNA abundance of AR and its target prostate-specific antigen within 12 h, and stimulated proteosomal degradation of AR. Oral administration of TIIA (25 mg/kg, once daily) retarded LNCaP xenograft growth and down-regulated tumor AR abundance in athymic nude mice. Conclusion: AR targeting action of tanshinones was distinct from Casodex and contributed to prostate cancer growth suppression in vitro and in vivo.
UR - http://www.scopus.com/inward/record.url?scp=84862826362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862826362&partnerID=8YFLogxK
U2 - 10.1007/s11095-012-0670-3
DO - 10.1007/s11095-012-0670-3
M3 - Article
C2 - 22281759
AN - SCOPUS:84862826362
SN - 0724-8741
VL - 29
SP - 1595
EP - 1608
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 6
ER -